Product Description
HCB301 is a tri-specific fusion protein: an engineered IgV domain of human SIRPalpha fused to an anti-PD-L1 (Ig) V domain and an engineered human TGFRII. This results in blocking the checkpoint CD47 simultaneously with T-lymphocyte checkpoint PD-L1 blocking while inhibiting the activities of TGF-mediated immune-suppression functions. HCB301 exhibits good safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no obvious abnormality of RBC or platelet levels was observed, and a unique differential binding to tumor cells vs. RBC binding and subsequent significant decreases in phagocytosis may potentially reduce patient’s risk of anemia, thrombocytopenia, or any other cytopenia while maintaining potent anti-tumor activities. (Sourced from: https://www.hanchorbio.com/news/2024/us_fda_clearance_of_ind_application_for_hcb301)
Mechanisms of Action: TGFb Inhibitor,PD-L1 Inhibitor,SIRPa Inhibitor
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FBD Biologics Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hodgkin Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HCB301-101 | P1 |
Not yet recruiting |
Hodgkin Lymphoma |
2026-08-31 |